Chlorothiazide Versus Metolazone in Hospitalized Patients with Heart

Total Page:16

File Type:pdf, Size:1020Kb

Chlorothiazide Versus Metolazone in Hospitalized Patients with Heart Chlorothiazide Versus Metolazone in Hospitalized Patients with Heart Failure Receiving Loop Diruetics Barry Nicholson, PharmD; Halley Gibson, PharmD, BCPS Lahey Hospital & Medical Center, Burlington, MA Background Baseline Characteristics Secondary Outcomes Results • Heart failure (HF) is the primary diagnosis in > 1 million hospitalizations annually Characteristic Metolazone Chlorothiazide p-value • Loop diuretics are first-line treatment for edema for most patients with HF, and Secondary Outcome Metolazone Chlorothiazide p-value (n=62) (n=59) thiazide diuretics may be used as an adjuvant option for additional diuresis1 (n=62) (n=59) • Previous trials have shown that oral metolazone is non-inferior to intravenous chlorothiazide with regards to safety and efficacy2,3 Age (years) ± SD 75.6 ± 12.1 74.8 ± 12.1 0.55 Hypokalemia within 24 hours 13 (21) 14 (23.7) 0.89 • There is currently no institution-specific policy to guide thiazide diuretic post-thiazide, n (%) Male, n (%) 40 (64.5) 34 (56.7) 0.55 selection in patients with heart failure at Lahey Hospital & Medical Center Hypokalemia within 72 hours 10 (16.1) 5 (8.5) 0.32 post-thiazide, n (%) Objective Weight (kg) ± SD 92 ± 32.8 95.5 ± 31.1 0.54 To evaluate the safety and efficacy of chlorothiazide versus metolazone for Hypomagnesemia within 24 hours 5 (8.1) 7 (11.9) 0.69 Non-ICU, n (%) 48 (77.4) 39 (65) 0.24 augmented diuresis in hospitalized heart failure patients receiving loop diuretics post-thiazide, n (%) Endpoints Progressive Care Unit, n (%) 12 (19.4) 3 (5.1) 0.07 Hypomagnesemia within 72 hours 9 (14.5) 6 (10.2) 0.66 post-thiazide, n (%) Primary Endpoint Change in net urine output (UOP) pre and post-initiation Intensive Care Unit, n (%) 2 (3.2) 17 (28.8) <0.01* of either study thiazide diuretic at 24 and 72 hours Length of Stay, days ± SD 14.7 ± 6.6 17 ± 11.8 0.2 Serum creatinine, mg/dL ± SD 2.2 ± 1.2 2.2 ± 1.1 0.91 Secondary Endpoints - Incidence of the following at 24 and 72 hours: # patients needing additional 27 (43.5) 37 (62.7) 0.05 1. Electrolyte abnormalities thiazide diuretic doses, n (%) 2. Hypotension Potassium, mEq/L ± SD 4.2 ± 0.8 4.1 ± 0.75 0.48 3. Acute kidney injury * p < 0.05 indicates statistical significance Magnesium, mg/dL ± SD 2.1 ± 0.3 2 ± 0.44 0.14 - Inotrope administered within 24 hours Conclusions - Progression to renal replacement therapy Furosemide dose equivalent within 360.6 ± 225.9 476.4 ± 305.1 0.02* 59% ● Both metolazone and chlorothiazide were found to be comparable with respect - Hospital length of stay 24 hours pre-thiazide, mg ± SD 43% - Number of patients needing additional thiazide doses to providing additional diuresis to heart failure patients who were already * p < 0.05 indicates31% statistical significance receiving loop diuretics Methods ● There was no significant differences in rates of adverse effects between patients Primary Efficacy Results in the metolazone and chlorothiazide groups • Retrospective chart review conducted from August, 2018 - February, 2020 • Descriptive statistics were calculated as mean ± standard deviation and were Limitations compared using two-sided independent t-tests, or Χ2, as appropriate • 51 patients needed in each study arm to detect a 500-mL difference in UOP ● Patients were able to receive ● More patients in the chlorothiazide ○ ɑ = 0.05, power of 80%, p < 0.05 indicates statistical significance subsequent doses of diuretics group required subsequent dosing ● Majority of ICU patients in ● Unbalanced loop diuretic dosing Inclusion Criteria Exclusion Criteria chlorothiazide group ● Retrospective, single center study •- Admitted patients ≥ 18 years old - Intubated at the time of first dose - Diagnosis of HF - History of a kidney transplant Future Directions - Loop diuretic given within 24 hours - Renal replacement therapy needed of either metolazone or prior to thiazide initiation Results will be shared with members of the Cardiology and Heart Failure divisions chlorothiazide initiation - Received initial doses of both with discussion to potentially risk-stratify use of metolazone to preferential use - Fluid intake and UOP data measured metolazone and chlorothiazide in non-ICU patients at least 24 hours before and 72 within 24 hours of each other Disclosures hours after thiazide administration * p < 0.05 indicates statistical significance Authors of this presentation have no financial disclosure or conflicts of interest References 1. Guideline for the Management of Heart Failure AHA 2013. 2. Moranville, M et. al Cardiovascular Therapeutics; 2015 3. Schulenberger, C et. al Pharmacotherapy; 2016 with the presented material. .
Recommended publications
  • Pediatric Pharmacotherapy
    Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 1, Number 10, October 1995 DIURETICS IN CHILDREN • Overview • Loop Diuretics • Thiazide Diuretics • Metolazone • Potassium Sparing Diuretics • Diuretic Dosages • Efficacy of Diuretics in Chronic Pulmonary Disease • Summary • References Pharmacology Literature Reviews • Ibuprofen Overdosage • Predicting Creatinine Clearance Formulary Update Diuretics are used for a wide variety of conditions in infancy and childhood, including the management of pulmonary diseases such as respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD)(1 -5). Both RDS and BPD are often associated with underlying pulmonary edema and clinical improvement has been documented with diuretic use.6 Diuretics also play a major role in the management of congestive heart failure (CHF), which is frequently the result of congenital heart disease (7). Other indications, include hypertension due to the presence of cardiac or renal dysfunction. Hypertension in children is often resistant to therapy, requiring the use of multidrug regimens for optimal blood pressure control (8). Control of fluid and electrolyte status in the pediatric population remains a therapeutic challenge due to the profound effects of age and development on renal function. Although diuretics have been used extensively in infants and children, few controlled studies have been conducted to define the pharmacokinetics and pharmacodynamics of diuretics in this population. Nonetheless, diuretic therapy has become an important part of the management of critically ill infants and children. This issue will review the mechanisms of action, monitoring parameters, and indications for use of diuretics in the pediatric population (1-5). Loop Diuretics Loop diuretics are the most potent of the available diuretics (4).
    [Show full text]
  • DIURETICS Diuretics Are Drugs That Promote the Output of Urine Excreted by the Kidneys
    DIURETICS Diuretics are drugs that promote the output of urine excreted by the Kidneys. The primary action of most diuretics is the direct inhibition of Na+ transport at one or more of the four major anatomical sites along the nephron, where Na+ reabsorption takes place. The increased excretion of water and electrolytes by the kidneys is dependent on three different processes viz., glomerular filtration, tubular reabsorption (active and passive) and tubular secretion. Diuretics are very effective in the treatment of Cardiac oedema, specifically the one related with congestive heart failure. They are employed extensively in various types of disorders, for example, nephritic syndrome, diabetes insipidus, nutritional oedema, cirrhosis of the liver, hypertension, oedema of pregnancy and also to lower intraocular and cerebrospinal fluid pressure. Therapeutic Uses of Diuretics i) Congestive Heart Failure: The choice of the diuretic would depend on the severity of the disorder. In an emergency like acute pulmonary oedema, intravenous Furosemide or Sodium ethacrynate may be given. In less severe cases. Hydrochlorothiazide or Chlorthalidone may be used. Potassium-sparing diuretics like Spironolactone or Triamterene may be added to thiazide therapy. ii) Essential hypertension: The thiazides usually sever as primary antihypertensive agents. They may be used as sole agents in patients with mild hypertension or combined with other antihypertensives in more severe cases. iii) Hepatic cirrhosis: Potassium-sparing diuretics like Spironolactone may be employed. If Spironolactone alone fails, then a thiazide diuretic can be added cautiously. Furosemide or Ethacrymnic acid may have to be used if the oedema is regractory, together with spironolactone to lessen potassium loss. Serum potassium levels should be monitored periodically.
    [Show full text]
  • Spironolactone Therapy in Infants with Congestive Heart Failure Secondary to Congenital Heart Disease
    Arch Dis Child: first published as 10.1136/adc.56.12.934 on 1 December 1981. Downloaded from Archives of Disease in Childhood, 1981, 56, 934-938 Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease SUSAN M HOBBINS, RODNEY S FOWLER, RICHARD D ROWE, AND ANDREW G KOREY Division of Cardiology, Department ofPaediatrics, Hospital for Sick Children, Toronto, and Department ofPaediatrics, University of Toronto, Canada SUMMARY The efficacy of treatment with spironolactone for congestive heart failure secondary to congenital heart disease was studied in 21 infants under 1 year of age. All received digoxin and chlorothiazide. In addition, group A (n = 10) was given supplements of potassium and group B (n = 11) received spironolactone. Daily clinical observations of vital signs, weight, hepatomegaly, and vomiting were recorded. Paired t test analysis showed significant reduction in liver size and weight (P< 01) and respiratory rate (P< 0 05) in group B, and less significant decreases in group A. The incidence of vomiting was slightly lower in group B. We conclude that the addition of spiro- nolactone hastens and enhances the response to standard treatment with digoxin and chlorothiazide in infants with congestive heart failure. Spironolactone, a pharmacological antagonist of the We excluded or withdrew from the study any adrenal mineralocorticoid,l has been used for some infant in whom any of the following was present copyright. years in the treatment of congestive heart failure or developed. (1) Renal disease or dysfunction, as (CHF). By competitively binding to specific nuclear shown by blood urea nitrogen >8-925 mmol/l macromolecules in the distal convoluted renal (25 mg/100ml) or hepatic disease or dysfunction.
    [Show full text]
  • Nephropharmacology for the Clinician
    Nephropharmacology for the Clinician Clinical Pharmacology in Diuretic Use David H. Ellison CJASN 14: 1248–1257, 2019. doi: https://doi.org/10.2215/CJN.09630818 Diuretics are among the most commonly prescribed Gastrointestinal Absorption of Diuretics drugs and, although effective, they are often used to The normal metabolism of loop diuretics is shown in treat patients at substantial risk for complications, Figure 2A. Furosemide, bumetanide, and torsemide are Departments of making it especially important to understand and absorbed relatively quickly after oral administration Medicine and appreciate their pharmacokinetics and pharmacody- (see Figure 2B), reaching peak concentrations within Physiology and – Pharmacology, namics (see recent review by Keller and Hann [1]). 0.5 2 hours (3,4); when administered intravenously, Oregon Health & Although the available diuretic drugs possess distinc- their effects are nearly instantaneous. The oral bioavail- Science University, tive pharmacokinetic and pharmacodynamic proper- ability of bumetanide and torsemide typically exceeds Portland, Oregon; and ties that affect both response and potential for adverse 80%, whereas that of furosemide is substantially lower, Renal Section, at approximately 50% (see Table 2) (5). Although the t Veterans Affairs effects, many clinicians use them in a stereotyped 1/2 Portland Health Care manner, reducing effectiveness and potentially in- of furosemide is short, its duration of action is longer System, Portland, creasing side effects (common diuretic side effects are when administered orally, as its gastrointestinal Oregon t listed in Table 1). Diuretics have many uses, but this absorption may be slower than its elimination 1/2. review will focus on diuretics to treat extracellular This is a phenomenon called “absorption-limited Correspondence: fluid (ECF) volume expansion and edema; the reader is kinetics” (3) and may explain the mnemonic that Dr.
    [Show full text]
  • MELT-HF Metolazone As Early Add on Therapy for Acute Decompensated
    MELT-HF MEtolazone as Early add on Therapy for acute decompensated Heart Failure. A single center pilot study. Muhammad A. Chaudhry, MD MELT-HF Protocol [Amendment 5.0; 17-Jan-2017] Page 1 of 10 INTRODUCTION Background Heart failure is a major source of morbidity, mortality and growing public health cost. In US, the number of congestive heart failure patients is more than 4 million with more than 550,000 new annually reported cases. The annual cost of heart failure management exceeds 35 billion dollars per year. The heart failure readmissions and average length of hospital stay cost approximately $11,000 per patient. Loop diuretics are used alone in the majority of cases to promote diuresis. An association of increased creatinine and increased risk of renal dysfunction, the cardiorenal syndrome, in the face of high dose loop diuretics has raised questions regarding the safety and toxicity of high dose loop diuretics. While the dose of diuretics is ubiquitous, little data exists to guide their use and many clinicians are uncertain as to when and how to initiate and limit therapy. In many cases, a “stepped approach” with oral loop diuretics advancing to intravenous and finally combination high dose diuretics is employed. PREVIOUS TRIALS DOSE( Diuretic strategies in patients with ADHF) Trial Prospective, randomized double blinded trial of 308 patients with ADHF. Showed that high dose diuretics (2.5 times the outpatient daily dose) were associated with improved urine output at 72 hours (3575± 2635 in low dose group vs. 4899±3479 in high dose group). There was no significant difference between the high and low dose groups in mean creatinine change (0.08±0.3 mg per deciliter in high-dose group as compared to 0.04±0.3 mg per deciliter in low-dose group, P=0.21.
    [Show full text]
  • Diuretic Renal Scintigraphy in Patients with Sulfonamide Allergies: Possible Alternative Use of Ethacrynic Acid
    J of Nuclear Medicine Technology, first published online October 15, 2015 as doi:10.2967/jnmt.115.161331 Diuretic Renal Scintigraphy in Patients with Sulfonamide Allergies: Possible Alternative Use of Ethacrynic Acid. Ba D. Nguyen, M.D. Michael C. Roarke, M.D. Jason Robert Young*, M.D. Ming Yang, M.D. Howard H. Osborn R.N. Department of Radiology, Mayo Clinic, Scottsdale, AZ (attributed to work) *Department of Radiology, Maricopa Integrated Health System, Phoenix, AZ Correspondence and first author: Ba D Nguyen, M.D., Department of Radiology, Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ 85259. Telephone: 480 3016865, Fax: 480 3014303, Email: [email protected] Word Count: 999 Financial Support: None Disclosures: Nothing to disclose Short running title: Ethacrynic Acid for Renal Scintigraphy Diuretic Renal Scintigraphy in Patients with Sulfonamide Allergies: Possible Alternative Use of Ethacrynic Acid. Abstract Furosemide may trigger life threatening sulfonamide cross-hypersensitivity reactions, posing an imaging decision dilemma for patients who need diuretic renal scintigraphy. Methods: The authors present the experience using ethacrynic acid as a non-sulfonamide alternative diuretic in five patients with discussion of diuretic molecular structure, potential side effects, protocol development and imaging results. Results: Diuretic renal scintigraphy using ethacrynic acid provided useful information about the obstructive syndrome status in all cases with no adverse clinical impact. Conclusion: Ethacrynic acid is a potential alternative to furosemide for patients with severe sulfonamide reactions. Key words: Ethacrynic Acid, Diuretic Renal Scintigraphy, Sulfonamide allergy. The objective of this essay is to raise awareness of ethacrynic acid as a possible alternative to furosemide for provocative diuretic renal scintigraphy.
    [Show full text]
  • Potassium and Magnesium-Sparing Diuretics
    Originalia Potassium and Magnesium-Sparing Diuretics M. P. Ryan Summary chez i) des rats non anesthesies avec une gebnis entspricht der unterschiedlichen Be­ charge saline ii) la clearance renale chez les handlung von Kalium und Magnesium im The renal handling of potassium and mag­ animaux anesthesies iii) des patients avec distalen Tubulus und im Sammelrohr. nesium and the effects of diuretics on these insuffisance cardiaque congestive chroni­ Auch bei Triamteren wurden magnesium­ processes are reviewed. Loop-blocking que. Dans des etudes sur I'animal, une rela­ sparende Eigenschaften nachgewiesen. Die diuretics cause major losses of both potas­ tion dose-reponse a ete etablie pour les ac­ Wirkungen von Aldosteron-Antagonisten sium and magnesium. Thiazide diuretics tions de I'amiloride dans la reduction de sind allerdings noch nicht so eingehend cause major losses of potassium while their !'excretion fractionnee du Mg et du K au nachgewiesen. effects on magnesium excretion are less well cours de la diurese induite par le furose­ established. Evidence has accumulated in mide. Les effets de l'amiloride sur !'excre­ recent years that the potassium-sparing tion du Mg sont moindres que ceux sur diuretics also exert magnesium-sparing !'excretion du K qui est compatible avec un Introduction properties. Experiments from our own traitement different de K et de Mg dans le laboratories and from other investigators tubule distal et le canal collecteur. L'triam­ Congestive heart failure is a disease are reviewed. Amiloride has been demons­ terene est I'diuretique peuvent avoir aussi trated to exert magnesium-sparing proper­ proprietes d'epargne du Mg. Lcs effets des which may be associated with dis­ ties in i) conscious saline-loaded rats ii) re­ antagonistes de I' aldosterone sur l'excretion turbances in the four main cations nal clearance studies in rats iii) congestive du Mg sont mains bien etablis que ceux de namely sodium, potassium, calcium heart failure patients.
    [Show full text]
  • Azosemide Is More Potent Than Bumetanide and Various Other Loop
    www.nature.com/scientificreports OPEN Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium- Received: 21 November 2017 Accepted: 14 June 2018 potassium-chloride-cotransporter Published: xx xx xxxx human variants hNKCC1A and hNKCC1B Philip Hampel 1,2, Kerstin Römermann1, Nanna MacAulay 3 & Wolfgang Löscher1,2 The Na+–K+–2Cl− cotransporter NKCC1 plays a role in neuronal Cl− homeostasis secretion and represents a target for brain pathologies with altered NKCC1 function. Two main variants of NKCC1 have been identifed: a full-length NKCC1 transcript (NKCC1A) and a shorter splice variant (NKCC1B) that is particularly enriched in the brain. The loop diuretic bumetanide is often used to inhibit NKCC1 in brain disorders, but only poorly crosses the blood-brain barrier. We determined the sensitivity of the two human NKCC1 splice variants to bumetanide and various other chemically diverse loop diuretics, using the Xenopus oocyte heterologous expression system. Azosemide was the most potent NKCC1 inhibitor (IC50s 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B), being about 4-times more potent than bumetanide. Structurally, a carboxylic group as in bumetanide was not a prerequisite for potent NKCC1 inhibition, whereas loop diuretics without a sulfonamide group were less potent. None of the drugs tested were selective for hNKCC1B vs. hNKCC1A, indicating that loop diuretics are not a useful starting point to design NKCC1B-specifc compounds. Azosemide was found to exert an unexpectedly potent inhibitory efect and as a non-acidic compound, it is more likely to cross the blood-brain barrier than bumetanide. Te Na+–K+–2Cl− cotransporter NKCC1 (encoded by SLC12A2) plays an important role in Cl- uptake in neu- rons both in developing brain and in adult sensory neurons1,2.
    [Show full text]
  • Drug Classes Other Diuretics
    DRUG CLASSES OTHER DIURETICS Loop diuretics and potassium sparing diuretics have limited roles in the management of hypertension although accumulating evidence suggests that potassium-sparing diuretics may have an important place in apparently resistant hypertension. LOOP DIURETICS Examples Bumetamide Furosemide Torasemide Mechanism of action Loop diuretics act on the nephron mainly in the thick ascending links of the Loop of Henle. Although loop diuretics have diuretic efficacy greater than that of thiazide or thiazide-like agents, effects on blood pressure are relatively brief and reflex stimulation of the renin-angiotensin system tends to counter the fall in blood pressure. Pharmacokinetics Loop diuretics are well absorbed after oral administration. Elimination is largely by the renal route with a small contribution from liver metabolism. Like thiazide and thiazide- like diuretics, the renal effects depend on access to the luminal side of the renal tubule; unlike thiazide and thiazide-like diuretics, loop diuretics retain some efficacy in renal impairment. Adverse effects As with thiazide and thiazide-like diuretics, these are mainly metabolic Hypokalaemia is even less common than with low-dose thiazides or thiazide-like diuretics Hyperglycaemia is less marked than with thiazide or thiazide-like diuretics 1 Urate retention risk of acute gout Hypocalcaemia due to increased renal clearance of calcium small risk of ureteric calculi Practical issues Bumetamide and furosemide have a rapid onset and short duration of action. Twice daily dosing is more effective in lowering blood pressure. However, persistent diuresis may limit utility. Torasemide has a longer duration of action and can be given once daily but metabolic complications, particularly hypokalaemia, are more marked than with other loop- diuretics.
    [Show full text]
  • Should We Switch from Bendrofluazide to Chlorthalidone As the Initial Treatment for Hypertension? a Review of the Available Medication
    ORIGINAL SCIENTIFIC PAPER SYSTEMatic REVIEW Should we switch from bendrofluazide to chlorthalidone as the initial treatment for hypertension? A review of the available medication Bruce Arroll MBChB, PhD, FRNZCGP; Henry Wallace Department of General Practice and Primary ABSTRACT Health Care, University of Auckland, Private Bag INTRODUCTION: Thiazide diuretics are commonly prescribed in the treatment of hypertension. 92019, Auckland 1142, However, thiazide diuretics may not all be equal in their ability to reduce cardiovascular New Zealand disease outcomes. AIM: To determine if bendroflumethiazide/bendrofluazide, the most commonly used diuretic for hypertension in New Zealand, is as effective as other diuretics in terms of cardiovascular disease outcomes. METHODS: Using recent reviews of thiazide-like (chlorthalidone or indapamide) and thiazide-type diuretics (hydrochlorothiazide and bendrofluazide) and a separate search of bendrofluazide, data on cardiovascular disease outcomes was extracted. RESULTS: Nineteen relevant papers with 21 comparisons were found. All thiazide-based diu- retics have been reported in at least one trial showing them to be more effective than placebo for cardiovascular disease outcomes, with the exception of chlorothiazide. There were no comparisons of bendrofluazide alone with other medications, but there were two studies with either bendrofluazide or hydrochlorothiazide compared withb -blockers; however, the pooled relative risk (RR) was not significant (RR = 1.10 (95% CI, 0.84–1.43)). For chlorthalidone, there were four comparisons with other medications, and the summary RR was statistically signifi- cant for cardiovascular disease outcomes (RR = 0.91 (95% CI, 0.85–0.98)). Chlorthalidone was significantly more effective for some cardiovascular disease outcomes when compared with doxazosin, amlodipine and lisinopril.
    [Show full text]
  • Which Diuretics Are Safe and Effective for Patients with a Sulfa Allergy?
    From the CLINIcAL InQUiRiES Family Physicians Inquiries Network Ron Healy, MD University of Washington, Which diuretics are safe Seattle; Alaska Family Medicine Residency, Anchorage and effective for patients Terry Ann Jankowski, MLS University of Washington, Seattle with a sulfa allergy? Evidence-based answer Diuretics that do not contain a sulfonamide subsequent allergic reactions to commonly group (eg, amiloride hydrochloride, used sulfonamide-containing diuretics eplerenone, ethacrynic acid, spironolactone, (eg, carbonic anhydrase inhibitors, loop and triamterene) are safe for patients with an diuretics, and thiazides) (strength of allergy to sulfa. The evidence is contradictory recommendation: C, based on case series ® as to whether a history Dowdenof allergy to Healthand poor Media quality case-control and cohort sulfonamide antibiotics increases the risk of studies). Copyright Clinical commentaryFor personal use only Are all sulfa drugs created equal? agents and off-patent, with no company Historical bromides commonly fall by the to take up their cause, no one has been FAST TRACK wayside as better evidence becomes willing to challenge outdated package Reasonable available. Who would have thought 15 insert warnings. years ago that we would be promoting As clinicians who regularly work evidence supports beta-blockers for patients with congestive without a net, we are accustomed to what many of us heart failure? prescribing medications in less than ideal are doing: Using Likewise, with closer inspection, we circumstances. Thankfully, reasonable cheap thiazides have learned that not all sulfa drugs are evidence is available to support what many created equal. The stereospecificity due of us are already doing—using cheap for patients to the absence of aromatic amines in thiazides for patients despite a history of with a history common diuretics means they are safe sulfa allergy.
    [Show full text]
  • Optimal Diuretic Strategies in Heart Failure
    517 Review Article on Heart Failure Update and Advances in 2021 Page 1 of 8 Optimal diuretic strategies in heart failure Sarabjeet S. Suri, Salpy V. Pamboukian Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, AL, USA Contributions: (I) Conception and design: SS Suri; (II) Administrative support: SV Pamboukian; (III) Provision of study materials or patients: Both authors; (IV) Collection and assembly of data: Both authors; (V) Data analysis and interpretation: Both authors; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors. Correspondence to: Dr. Sarabjeet S. Suri, MD. University of Alabama at Birmingham, 1900 University Blvd, THT 321, Birmingham, AL 35223, USA. Email: [email protected]. Abstract: Heart failure (HF) is one of the major causes of morbidity and mortality in the world. According to a 2019 American Heart Association report, about 6.2 million American adults had HF between 2013 and 2016, being responsible for almost 1 million admissions. As the population ages, the prevalence of HF is anticipated to increase, with 8 million Americans projected to have HF by 2030, posing a significant public health and financial burden. Acute decompensated HF (ADHF) is a syndrome characterized by volume overload and inadequate cardiac output associated with symptoms including some combination of exertional shortness of breath, orthopnea, paroxysmal nocturnal dyspnea (PND), fatigue, tissue congestion (e.g., peripheral edema) and decreased mentation. The pathology is characterized by hemodynamic abnormalities that result in autonomic imbalance with an increase in sympathetic activity, withdrawal of vagal activity and neurohormonal activation (NA) resulting in increased plasma volume in the setting of decreased sodium excretion, increased water retention and in turn an elevation of filling pressures.
    [Show full text]